Austria
· Delayed Price · Currency is EUR Marinomed Biotech AG Statistics
Total Valuation
Marinomed Biotech AG has a market cap or net worth of EUR 26.44 million. The enterprise value is 46.33 million.
| Market Cap | 26.44M |
| Enterprise Value | 46.33M |
Important Dates
The next estimated earnings date is Wednesday, April 16, 2025.
| Earnings Date | Apr 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Marinomed Biotech AG has 1.69 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 1.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.00% |
| Owned by Institutions (%) | 25.39% |
| Float | 1.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.75 |
| EV / Sales | 7.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.56 |
Financial Position
The company has a current ratio of 1.87
| Current Ratio | 1.87 |
| Quick Ratio | 1.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.49 |
| Interest Coverage | -2.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.03% |
| Return on Capital (ROIC) | -31.38% |
| Revenue Per Employee | 150,045 |
| Profits Per Employee | -156,027 |
| Employee Count | 52 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 5.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.53% in the last 52 weeks. The beta is 0.06, so Marinomed Biotech AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -49.53% |
| 50-Day Moving Average | 10.84 |
| 200-Day Moving Average | 12.46 |
| Relative Strength Index (RSI) | 65.28 |
| Average Volume (20 Days) | 2,226 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marinomed Biotech AG had revenue of EUR 6.60 million and -6.87 million in losses.
| Revenue | 6.60M |
| Gross Profit | 411,300 |
| Operating Income | -6.58M |
| Pretax Income | -6.86M |
| Net Income | -6.87M |
| EBITDA | -6.18M |
| EBIT | -6.58M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 1.86 million in cash and 21.75 million in debt, giving a net cash position of -19.89 million or -11.74 per share.
| Cash & Cash Equivalents | 1.86M |
| Total Debt | 21.75M |
| Net Cash | -19.89M |
| Net Cash Per Share | -11.74 |
| Equity (Book Value) | -11.84M |
| Book Value Per Share | n/a |
| Working Capital | 2.26M |
Cash Flow
In the last 12 months, operating cash flow was -4.72 million and capital expenditures -128,500, giving a free cash flow of -4.85 million.
| Operating Cash Flow | -4.72M |
| Capital Expenditures | -128,500 |
| Free Cash Flow | -4.85M |
| FCF Per Share | -2.86 |
Margins
Gross margin is 6.23%, with operating and profit margins of -99.74% and -103.99%.
| Gross Margin | 6.23% |
| Operating Margin | -99.74% |
| Pretax Margin | -103.93% |
| Profit Margin | -103.99% |
| EBITDA Margin | -93.66% |
| EBIT Margin | -99.74% |
| FCF Margin | n/a |
Dividends & Yields
Marinomed Biotech AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -18.33% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Marinomed Biotech AG has an Altman Z-Score of -6.44. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.44 |
| Piotroski F-Score | n/a |